Agenus inc (AGEN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net income (loss)

-111,560

-162,044

-120,692

-126,995

-

-

-

-

-

-

-

Net loss

-

-

-

-

-87,881

-42,486

-30,072

-11,324

-23,276

-21,906

-30,317

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

6,662

6,288

6,006

4,947

1,957

1,583

586

1,622

2,252

3,437

4,108

Share-based compensation

9,892

7,625

12,429

13,188

7,438

4,672

4,127

4,303

2,646

3,151

3,130

Non-cash royalty revenue

30,424

17,309

-

-

-

-

-

-

-

-

-

Non-cash interest expense

42,201

24,599

18,242

16,530

5,626

619

1,820

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

3,141

4,167

4,053

-4,014

Loss on disposal of assets

-58

-145

-24

-14

-

-4

-59

-11

-37

-161

-51

Change in fair value of contingent obligations

5,805

-1,335

-3,188

1,953

13,567

3,579

-

-

-

-

-

Gain on issuance of stock for settlement of milestone obligation

-

-

566

-

-

-

-

-

-

-

-

Change in fair value of contingent obligations

-

-

-

-

-

-

-

0

-

-

-

In-process research and development purchase

-

-

-

-

12,245

-

-

-

-

-

-

Loss on modification of debt

-

-10,767

-

-

-154

-

-3,322

0

0

2,761

2,653

Bargain purchase

-

-

-

-

1,522

-

-

-

-

-

-

Deferred tax benefit

-

-

-

-

-5,387

-

-

-

-

-

-

Gain on sale of investment

-

-

-

-

-

-

355

0

0

-

-

Change in fair value of assumed convertible notes

-

-

-

-

-

201

-

0

-

-

-

Asset impairment

-

-

-

-

-

-

-

-

-

629

-

Intangible asset impairment

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of derivative liability

-

-

-

-

-

-

291

0

0

1,910

47

Changes in operating assets and liabilities:
Loss on monetization of receivable

-

-

-

-

-

-

-

-

-

-

317

Accounts receivable

15,355

-196

-10,217

1,549

9,331

-1

-551

552

-35

35

0

Inventories

-55

-24

-9

-

-7

95

-16

-4

-6

-297

97

Prepaid expenses

-11,792

8,210

8,453

650

703

254

112

9

-168

-47

141

Accounts payable

-234

5,366

1,646

419

2,668

-45

189

-181

105

-198

296

Deferred revenue

53,900

-397

-2,722

-3,939

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

15,957

-3,610

-1,474

2,707

-1,531

674

-440

Accrued liabilities and other current liabilities

7,097

3,303

-4,849

18,275

9,565

-1,316

1,916

542

-269

-246

-2,120

Other operating assets and liabilities

-1,429

113

2,329

2,155

11,538

685

-183

-747

591

152

293

Net cash (used in) provided by operating activities

-18,682

-131,095

-94,226

-79,960

-

-

-

1,012

-16,248

-14,758

-24,193

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-47,175

-38,234

-19,532

-

-

-

-

Cash paid for acquisitions

-

-

-

-

7,182

-

-

-

-

-

-

Proceeds from maturities of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

30,000

Collection of receivable from sale of patent applications

-

-

-

-

-

-

-

-

-

-

2,337

Proceeds from sale of plant and equipment

-

6

120

-

-

-

-

-

23

50

53

Cash acquired in acquisition

-

-

-

-

-

514

-

0

-

-

-

Purchases of plant and equipment

4,657

3,597

3,120

12,519

3,591

2,819

813

103

54

130

243

Proceeds from maturities of available-for-sale securities

-

-

-

-

-

-

-

-

5,000

40,000

-

Purchases of available-for-sale securities

-

-

14,936

54,884

34,993

14,507

-

0

4,998

29,989

29,986

Proceeds from sale of available-for-sale securities

-

-

20,000

85,000

14,534

-

450

-

-

-

-

Net cash used in investing activities

-

-

-

-

-31,232

-16,813

-363

-

-

-

-

Proceeds from sale of available-for-sale securities

-

-

-

-

-

-

-

0

0

-

-

Net cash used in investing activities

-4,657

-3,591

2,064

17,596

-

-

-

-103

-29

9,930

2,160

Cash flows from financing activities:
Net proceeds from sale of equity

30,000

44,919

65,560

2,167

109,669

56,792

26,462

10,464

7,980

11,525

-

Proceeds from employee stock purchases and option exercises

1,643

1,234

987

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

0

141

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

18,572

Payment of long-term debt

-

-

-

-

-

-

-

-

-

-

255

Proceeds from employee stock purchases and option exercises

-

-

-

1,183

1,975

251

104

78

82

48

16

Purchase of treasury shares to satisfy tax withholdings

-

-

527

667

-

-

-

-

-

-

-

Financing of plant and equipment

-

-

-

-

-

39

53

-

-

-

-

Financing of plant and equipment

-

-

-

-

-

-

-

-38

-28

0

-

Proceeds from issuance of long-term debt

-

-

15,000

-

109,000

-

10,000

-

-

-

-

Debt issuance costs

-

-

150

-

1,774

-

177

-

-

-

-

Proceeds from sale of future royalties

-

204,878

-

-

-

-

-

-

-

-

-

Transaction costs from sale of future royalties and milestones

-

494

-

-

-

-

-

-

-

-

-

Repayments of debt

-

161,847

-

-

1,111

3,333

555

-

-

-

-

Payment of contingent purchase price consideration

-

-

-

-

8,180

-

-

-

-

-

-

Payment under a purchase agreement for in-process research and development

-

-

-

5,000

-

-

-

-

-

-

-

Treasury stock received to satisfy minimum tax withholding requirements

-

-

-

-

-

-

-

-

-

-

54

Payment of preferred stock dividends

-

-

-

-

-

460

-

592

790

790

790

Payment of contingent royalty obligation

-

-

-

-

20,000

400

-

0

-

-

-

Payment of finance lease obligation

320

283

331

144

-

-

-

-

-

-

-

Payments of convertible notes

-

-

-

-

-

-

10,000

0

0

-

-

Net cash provided by financing activities

-

-

-

-

189,579

52,810

25,780

-

-

-

-

Payments of contingent royalty obligation

-

-

-

-

20,000

-

-

0

-

-

-

Payments of long-term debt

-

-

-

-

-

-

-

-100

0

-6,240

-

Debt issuance costs

-

-

-

-

-

-

-

0

0

-

-

Proceeds from Issuance of Debt

-

-

-

-

-

-

-

0

0

-

-

Net cash provided by financing activities

31,323

128,286

80,539

-2,461

-

-

-

9,811

7,244

4,543

17,630

Effect of exchange rate changes on cash

770

-733

362

-429

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

8,754

-7,133

-11,261

-65,254

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-183

599

-

0

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

110,988

-1,637

5,883

10,720

-9,034

-284

-4,402

Supplemental cash flow information:
Cash paid for interest

1,224

1,171

1,120

1,120

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

1,053

675

579

1,573

12

1,122

-

Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities

1,242

300

968

695

105

-

-

-

-

-

-

Issuance of senior secured convertible notes as payment in-kind for interest

-

-

-

-

-

-

-

-

-

-

2,418

Issuance of common stock

-

-

-

-

-

-

-

-

-

-

14,134

Lease right-of-use assets obtained in exchange for new operating lease liabilities

3,017

-

-

-

-

-

-

-

-

-

-

Issuance of common stock, $0.01 par value, for acquisition of 4-Antibody AG

-

-

-

-

-

-

-

0

-

-

-

Contingent purchase price consideration

-

-

-

-

-

9,721

-

0

-

-

-

Issuance of senior secured convertible notes as payment in-kind for interest

-

-

-

-

-

-

-

1,499

2,829

2,615

-

Deemed dividend on series A convertible preferred stock

-

-

-

-

-

-

2,906

0

0

-

-

Issuance of common stock, $0.01 par value, as payment of long-term debt including accrued and unpaid interest

-

-

-

-

-

953

11,275

-

-

-

-

Contingent royalty obligation

-

-

-

-

-

-

19,090

0

0

-

-

Elimination of non-controlling interest

-

-

-

-

-

-

5,580

0

0

-

-

Interest Paid

-

-

-

-

-

-

-

-

-

-

1,573

Convertible note adjustment to equity for conversion option

-

-

-

-

-

-

-

-

5,580

0

0

Reclassification of derivative liability into equity

-

-

-

-

-

-

-

-

755

0

0

Long-term debtequipment financing

-

-

-

-

-

-

-

-

171

0

-

Issuance of common stock, $0.01 par value, as payment of long-term debt

-

-

-

-

-

-

-

0

0

10,361

-

Note Payable for Purchase of plant and equipment

-

-

-

-

-

-

-

-

-

-

0

Series C-1 Convertible Preferred Stock [Member]
Net proceeds from sale of C-1 Preferred Stock

-

39,879

-

-

-

-

-

-

-

-

-

SECANT Yeast Display technology [Member]
Issuance of common stock

-

-

3,548

-

-

-

-

-

-

-

-

Milestone obligation [Member]
Issuance of common stock

-

-

1,486

886

-

-

-

-

-

-

-

Directors Compensation [Member]
Issuance of common stock

-

-

-

161

-

-

-

-

-

-

-

Payment to Consultant [Member]
Issuance of common stock

81

50

-

-

-

-

-

-

-

-

-